New safety study for prostate cancer drug in vulnerable patients
NCT ID NCT07169825
Summary
This study aims to measure how much radiation from Pluvicto therapy reaches tumors and healthy organs in prostate cancer patients whose kidneys or bone marrow aren't working properly. Researchers will track 25 patients to understand the safety and side effects of this treatment in this specific group. The goal is to personalize future radiation doses for patients with these health complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LU-177 PSMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.